ArticleBMC cancer2025
Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy - a pilot study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trial
- Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era.Current hematologic malignancy reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasurement of health-related quality of life (HRQoL) in patients with melanoma under immune checkpoint inhibitor therapy (ICI) under routine conditions and in survivorship is insufficient due to the absence of data and therapy-specific instruments in clinical trials. This pilot study aimed to collect and compare data on symptom burden and HRQoL in patients during and after ICI therapy. The benefit of a treatment-/disease-specific item list compared to a general-oncologic HRQoL instrument was examined. The results are intended to be used for planning a longitudinal study.
methodsThis cross-sectional, monocentric, questionnaire-based study included patients with melanoma stages II-IV treated at the University Hospital Dresden, Germany. HRQoL was measured in a treatment group (ongoing ICI therapy) and a survivor group (minimum one year therapy- and relapse-free after ICI). The treatment group was interviewed with the cancer-generic EORTC QLQ-C30 and the survivor group with the EORTC SURV100, both consisting of different scales (range 0-100). Hereby, an elevated HRQoL score indicates a better HRQoL. Additionally, a treatment-/disease-specific PRO-CTCAE item list was conducted in both groups. We performed descriptive and exploratory analysis aiming to identify and compare symptom burden in both groups.
resultsGeneral health measured with EORTC C30/SURV100 in the treatment group (73 patients) was marginally lower than in the survivor group (26 patients) with a mean score of 61.0 (SD ± 21) vs. 67.0 (SD ± 21), which implies descriptively lower HRQoL scores in the treatment group than in clinical trials and population norm data. With almost similar demographic-clinical characteristics, the treatment group frequently reported pruritus and xerostomia, while survivors frequently reported aching joints, memory loss and a considerable emotional burden. The high prevalence of xerosis cutis, fatigue and sexual dysfunction was observed across both groups. In both groups, the specific PRO-CTCAE identified further relevant symptoms than the general instruments.
conclusionsNeeds of patients during and after ICI therapy appear to differ with an assumed remaining symptom burden in survivors of melanoma. For measuring HRQoL a therapy-/disease-specific instrument should be considered. Rising numbers of patients undergoing ICI therapy and survivors underscore the need for comprehensive data on HRQoL and specific aspects of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.